{"id":"W1998912113","doi":"10.1007/s00280-015-2682-2","title":"Open-label phase 1b study of FOLFIRI plus cetuximab plus IMO-2055 in patients with colorectal cancer who have progressed following chemotherapy for advanced or metastatic disease","year":2015,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Immune Response and Inflammation","field":"Immunology and Microbiology","cited_by":21,"is_retracted":false,"has_abstract":false,"ca_institutions":"Georgetown Hospital","funders":"National Center for Advancing Translational Sciences; National Center for Research Resources; EMD Serono; National Institutes of Health","keywords":"Medicine; FOLFIRI; Cetuximab; Irinotecan; Colorectal cancer; Gastroenterology; Folinic acid; Neutropenia; Internal medicine; Adverse effect; Phases of clinical research; Chemotherapy; Pharmacology; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001397637,0.002151696,0.003443462,0.0005851321,0.0007010214,0.001351925,0.001169972,0.002018047,0.006945177],"category_scores_gemma":[0.0009419395,0.001024702,0.002187764,0.0005146938,0.001735048,0.001540982,0.0004250941,0.005425849,0.0017311],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001474116,"about_ca_system_score_gemma":0.002047934,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002423462,"about_ca_topic_score_gemma":0.007186415,"domain_scores_codex":[0.9995373,0.0001680654,0.00001585419,0.00010153,0.00002915915,0.0001479891],"domain_scores_gemma":[0.9991779,0.0001164871,0.000122915,0.0000647135,0.00004637833,0.0004716422],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.9017195,0.05244976,0.001586942,0.0004267734,0.0006872466,0.00008472226,0.0001455237,0.001306544,0.008649384,0.0001638896,0.001803855,0.030976],"study_design_scores_gemma":[0.6360468,0.3556071,0.0045362,0.00002172881,0.0002949779,0.00007544026,0.0000650919,0.0006875652,0.0010927,0.0001351487,0.001408949,0.00002830813],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9898916,0.001927234,0.0006828427,0.0007021414,0.0003179298,0.00287084,0.00142683,0.0001394257,0.002041098],"genre_scores_gemma":[0.9844949,0.001850042,0.001957333,0.001179416,0.000297034,0.002731,0.002568403,0.00004318628,0.004878717],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006945177,"threshold_uncertainty_score":0.02323389,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04090778995048399,"score_gpt":0.3827514266994293,"score_spread":0.3418436367489453,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}